Sana Biotechnology Faces Analyst Downgrade Amid Heightened FDA Gene Therapy Scrutiny
Feb 13, 2026
Sana Biotechnology received an analyst downgrade as the FDA increases regulatory scrutiny on gene therapies, raising questions about the company's cash runway and clinical progress ahead of its mid-March 2026 quarterly update.